NO20013452L - Benzoheterocykler og deres anvendelse som MEK-inhibitorer - Google Patents

Benzoheterocykler og deres anvendelse som MEK-inhibitorer

Info

Publication number: NO20013452L
Authority: NO; Norway
Prior art keywords: mek inhibitors; heterocycles; benzo; benzo heterocycles; mek
Prior art date: 1999-01-13

Application number

NO20013452A

Other languages

English (en)

Other versions

NO20013452D0 (no

Inventor

Stephen Douglas Barrett

Alexander James Bridges

Haile Tecle

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-13

Filing date

2001-07-12

Publication date

2001-07-12

2001-07-12 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2001-07-12 Publication of NO20013452D0 publication Critical patent/NO20013452D0/no

2001-07-12 Publication of NO20013452L publication Critical patent/NO20013452L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Virology (AREA)
Transplantation (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

NO20013452A 1999-01-13 2001-07-12 Benzoheterocykler og deres anvendelse som MEK-inhibitorer NO20013452L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11587399P	1999-01-13	1999-01-13
US12255399P	1999-03-02	1999-03-02
PCT/US1999/030483 WO2000042022A1 (en)	1999-01-13	1999-12-21	Benzoheterocycles and their use as mek inhibitors

Publications (2)

Publication Number	Publication Date
NO20013452D0 NO20013452D0 (no)	2001-07-12
NO20013452L true NO20013452L (no)	2001-07-12

Family

ID=26813662

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013452A NO20013452L (no)	1999-01-13	2001-07-12	Benzoheterocykler og deres anvendelse som MEK-inhibitorer

Country Status (31)

Country	Link
US (1)	US6469004B1 (no)
EP (1)	EP1144385B1 (no)
JP (1)	JP4621355B2 (no)
KR (1)	KR20020002370A (no)
CN (1)	CN1177830C (no)
AP (1)	AP2001002224A0 (no)
AT (1)	ATE302193T1 (no)
AU (1)	AU2203700A (no)
BG (1)	BG105800A (no)
BR (1)	BR9916904A (no)
CA (1)	CA2355470C (no)
CZ (1)	CZ20012498A3 (no)
DE (1)	DE69926800T2 (no)
EA (1)	EA200100772A1 (no)
EE (1)	EE200100373A (no)
ES (1)	ES2247859T3 (no)
GE (1)	GEP20032922B (no)
HK (1)	HK1041697A1 (no)
HR (1)	HRP20010524A2 (no)
HU (1)	HUP0105113A3 (no)
ID (1)	ID30439A (no)
IL (1)	IL144214A0 (no)
IS (1)	IS5976A (no)
MA (1)	MA26771A1 (no)
NO (1)	NO20013452L (no)
NZ (1)	NZ513433A (no)
OA (1)	OA11746A (no)
SK (1)	SK9832001A3 (no)
TR (1)	TR200102030T2 (no)
WO (1)	WO2000042022A1 (no)
YU (1)	YU49401A (no)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010068738A1 (en)	2008-12-10	2010-06-17	Dana-Farber Cancer Institute, Inc.	Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en)	2010-02-25	2011-09-01	Dana-Farber Cancer Institute, Inc.	Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en)	2012-05-08	2013-11-14	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2350234A1 (en) *	1999-01-07	2000-07-13	Alexander James Bridges	Treatment of asthma with mek inhibitors
US7030119B1 (en)	1999-07-16	2006-04-18	Warner-Lambert Company	Method for treating chronic pain using MEK inhibitors
CN1358094A (zh) *	1999-07-16	2002-07-10	沃尼尔·朗伯公司	用mek抑制剂治疗慢性疼痛的方法
US7001905B2 (en)	2000-03-15	2006-02-21	Warner-Lambert Company	Substituted diarylamines as MEK inhibitors
IL153817A0 (en) *	2000-07-19	2003-07-31	Warner Lambert Co	Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2478374C (en)	2002-03-13	2009-01-06	Eli M. Wallace	N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478534A1 (en) *	2002-03-13	2003-09-25	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as mek inhibitors
US20050004186A1 (en) *	2002-12-20	2005-01-06	Pfizer Inc	MEK inhibiting compounds
US20050049276A1 (en) *	2003-07-23	2005-03-03	Warner-Lambert Company, Llc	Imidazopyridines and triazolopyridines
WO2005009975A2 (en)	2003-07-24	2005-02-03	Warner-Lambert Company Llc	Benzimidazole derivatives as mek inhibitors
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
EP1660090B1 (en)	2003-08-14	2012-11-21	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
US7144907B2 (en)	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en)	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
WO2005028426A1 (ja) *	2003-09-19	2005-03-31	Chugai Seiyaku Kabushiki Kaisha	新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
MY142589A (en)	2003-09-22	2010-12-15	S Bio Pte Ltd	Benzimidazole derivatives : preparation and pharmaceutical applications
CN100594212C (zh) *	2003-10-21	2010-03-17	沃纳-兰伯特公司	N-[(r)-2,3-二羟基-丙氧基]-3,4-二氟-2-(2-氟-4-碘苯基氨基)-苯甲酰胺的多晶型物
US7732616B2 (en) *	2003-11-19	2010-06-08	Array Biopharma Inc.	Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
JP4869075B2 (ja)	2003-11-19	2012-02-01	アレイバイオファーマ、インコーポレイテッド	Ｍｅｋの複素環阻害剤及びその使用方法
US7517994B2 (en) *	2003-11-19	2009-04-14	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0416852A (pt) *	2003-11-21	2007-02-27	Array Biopharma Inc	inibidores da quinase akt
CA2548172A1 (en)	2003-12-04	2005-06-23	Vertex Pharmaceuticals Incorporated	Quinoxalines useful as inhibitors of protein kinases
US20050171182A1 (en) *	2003-12-11	2005-08-04	Roger Briesewitz	Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
MY144232A (en)	2004-07-26	2011-08-15	Chugai Pharmaceutical Co Ltd	5-substituted-2-phenylamino benzamides as mek inhibitors
JP2008516939A (ja) *	2004-10-15	2008-05-22	アストラゼネカアクチボラグ	化学化合物
AR051248A1 (es)	2004-10-20	2007-01-03	Applied Research Systems	Derivados de 3-arilamino piridina
RU2500673C2 (ru)	2005-05-18	2013-12-10	Астразенека Аб	Гетероциклические ингибиторы мек и способы их применения
BRPI0612306A2 (pt)	2005-06-23	2010-11-03	Array Biopharma Inc	processo snar para preparar composto de benzimidazol
ES2567133T3 (es)	2005-06-23	2016-04-20	Array Biopharma, Inc.	Proceso para preparar compuestos de benzoimidazol
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
EP1934174B1 (en) *	2005-10-07	2011-04-06	Exelixis, Inc.	Azetidines as mek inhibitors for the treatment of proliferative diseases
PL2090575T3 (pl)	2005-11-15	2011-09-30	Array Biopharma Inc	Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy
GB0601962D0 (en)	2006-01-31	2006-03-15	Ucb Sa	Therapeutic agents
EP2025347A4 (en)	2006-05-15	2010-08-11	Takeda Pharmaceutical	PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
WO2008006025A1 (en)	2006-07-06	2008-01-10	Array Biopharma Inc.	Dihydrofuro pyrimidines as akt protein kinase inhibitors
PL2049500T3 (pl)	2006-07-06	2012-02-29	Array Biopharma Inc	Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
US8063050B2 (en)	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006039A1 (en)	2006-07-06	2008-01-10	Array Biopharma Inc.	Dihydrothieno pyrimidines as akt protein kinase inhibitors
CA2660963A1 (en) *	2006-08-21	2008-02-28	Genentech, Inc.	Aza-benzothiophenyl compounds and methods of use
ZA200901009B (en) *	2006-08-21	2010-05-26	Genentech Inc	Aza-benzothiophenyl compounds and methods of use
RU2444524C2 (ru) *	2006-08-21	2012-03-10	Дженентек, Инк.	Азабензотиофенильные соединения и способы применения
WO2008024725A1 (en) *	2006-08-21	2008-02-28	Genentech, Inc.	Aza-benzofuranyl compounds and methods of use
JP5311673B2 (ja)	2006-12-14	2013-10-09	エグゼリクシス，インコーポレイテッド	Ｍｅｋ阻害剤の使用方法
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
WO2008148034A1 (en) *	2007-05-25	2008-12-04	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors
EP2404907B1 (en)	2007-07-05	2015-01-14	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
BRPI0813999A2 (pt)	2007-07-05	2019-10-01	Array Biopharma Inc	ciclopentanos de pirimidil como inibidores de akt proteína cinase
PL2222675T3 (pl) *	2007-12-19	2014-02-28	Genentech Inc	5-anilinoimidazopirydyny i sposoby zastosowania
AU2009204019B2 (en)	2008-01-09	2014-02-20	Array Biopharma Inc.	Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
KR101624753B1 (ko)	2008-01-09	2016-05-26	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 저해물질로서의 수산화된 피리미딜 시클로펜탄
DK2307376T3 (en)	2008-08-04	2016-01-11	Merck Patent Gmbh	NOVEL phenylamino ISONIKOTINAMIDFORBINDELSER
WO2010051933A2 (en)	2008-11-10	2010-05-14	Bayer Schering Pharma Aktiengesellschaft	Substituted sulphonamido phenoxybenzamides
CA2777071A1 (en)	2009-10-21	2011-04-28	Bayer Pharma Aktiengesellschaft	Substituted halophenoxybenzamide derivatives
CA2777430A1 (en)	2009-10-21	2011-04-28	Bayer Pharma Aktiengesellschaft	Substituted benzosulphonamides
US8962606B2 (en)	2009-10-21	2015-02-24	Bayer Intellectual Property Gmbh	Substituted benzosulphonamides
AU2011224410B2 (en)	2010-03-09	2015-05-28	Dana-Farber Cancer Institute, Inc.	Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
JP5945532B2 (ja)	2010-04-21	2016-07-05	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9045429B2 (en)	2010-10-29	2015-06-02	Bayer Intellectual Property Gmbh	Substituted phenoxypyridines
CN102020651B (zh)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-芳基氨基吡啶酮甲酰胺mek抑制剂
BR112013025397A2 (pt)	2011-04-01	2019-09-24	Deepak Sampath	combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero
CA2831922C (en)	2011-04-01	2019-12-31	Genentech, Inc.	Combinations of akt inhibitor compounds and vemurafenib, and methods of use
ES2597052T3 (es)	2011-05-25	2017-01-13	Université Paris Descartes	Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
ES2396764B1 (es)	2011-11-02	2013-12-19	Universidad Autónoma de Madrid	FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
CN103204827B (zh)	2012-01-17	2014-12-03	上海科州药物研发有限公司	作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
CA2874905A1 (en)	2012-05-31	2013-12-05	Bayer Pharma Aktiengesellschaft	Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
HRP20180670T1 (hr)	2012-10-12	2018-07-13	Exelixis Inc.	Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
AR099630A1 (es) *	2012-10-19	2016-08-10	Novartis Ag	Preparación de un inhibidor de mek y formulación que lo comprende
WO2015038704A1 (en)	2013-09-11	2015-03-19	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Compositions for preparing cardiomyocytes
EP3094736A4 (en)	2014-01-14	2017-10-25	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN104774188B (zh) *	2014-01-15	2019-10-11	江苏恒瑞医药股份有限公司	苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN105384754B (zh) *	2014-09-02	2018-04-20	上海科州药物研发有限公司	作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
AU2015328411C1 (en)	2014-10-06	2022-03-03	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr)	2015-03-31	2018-02-06	Massachusetts Gen Hospital	Molécules à auto-assemblage pour l'administration ciblée de médicaments
WO2017033113A1 (en)	2015-08-21	2017-03-02	Acerta Pharma B.V.	Therapeutic combinations of a mek inhibitor and a btk inhibitor
WO2017106492A1 (en) *	2015-12-18	2017-06-22	Ignyta, Inc.	Combinations for the treatment of cancer
AR108257A1 (es)	2016-05-02	2018-08-01	Mei Pharma Inc	Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
EP4073102A4 (en)	2019-12-12	2024-05-08	Ting Therapeutics LLC	Compositions and methods for the prevention and treatment of hearing loss
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN114478447B (zh) *	2020-11-13	2024-12-13	江苏恒瑞医药股份有限公司	苯并含氧环类衍生物、其制备方法及其在医药上的应用
TW202342018A (zh)	2022-03-04	2023-11-01	美商奇奈特生物製藥公司	Mek激酶抑制劑
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5525625A (en)	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU5610398A (en) *	1997-02-28	1998-09-18	Warner-Lambert Company	Method of treating or preventing septic shock by administering a mek inhibitor
JP2002511092A (ja)	1997-07-01	2002-04-09	ワーナー−ランバート・コンパニー	４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用
US6310060B1 (en)	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
JP2000204079A (ja) *	1999-01-13	2000-07-25	Warner Lambert Co	ジアリ―ルアミン

1999
- 1999-12-21 IL IL14421499A patent/IL144214A0/xx unknown
- 1999-12-21 CZ CZ20012498A patent/CZ20012498A3/cs unknown
- 1999-12-21 DE DE69926800T patent/DE69926800T2/de not_active Expired - Lifetime
- 1999-12-21 EE EEP200100373A patent/EE200100373A/xx unknown
- 1999-12-21 ID IDW00200101730A patent/ID30439A/id unknown
- 1999-12-21 CA CA002355470A patent/CA2355470C/en not_active Expired - Fee Related
- 1999-12-21 CN CNB998156310A patent/CN1177830C/zh not_active Expired - Fee Related
- 1999-12-21 HU HU0105113A patent/HUP0105113A3/hu unknown
- 1999-12-21 KR KR1020017008822A patent/KR20020002370A/ko not_active Withdrawn
- 1999-12-21 AP APAP/P/2001/002224A patent/AP2001002224A0/en unknown
- 1999-12-21 BR BR9916904-5A patent/BR9916904A/pt not_active Application Discontinuation
- 1999-12-21 HK HK02103390.8A patent/HK1041697A1/zh unknown
- 1999-12-21 WO PCT/US1999/030483 patent/WO2000042022A1/en not_active Ceased
- 1999-12-21 ES ES99966521T patent/ES2247859T3/es not_active Expired - Lifetime
- 1999-12-21 NZ NZ513433A patent/NZ513433A/en unknown
- 1999-12-21 EA EA200100772A patent/EA200100772A1/ru unknown
- 1999-12-21 YU YU49401A patent/YU49401A/sh unknown
- 1999-12-21 EP EP99966521A patent/EP1144385B1/en not_active Expired - Lifetime
- 1999-12-21 HR HR20010524A patent/HRP20010524A2/hr not_active Application Discontinuation
- 1999-12-21 SK SK983-2001A patent/SK9832001A3/sk unknown
- 1999-12-21 JP JP2000593590A patent/JP4621355B2/ja not_active Expired - Fee Related
- 1999-12-21 AT AT99966521T patent/ATE302193T1/de not_active IP Right Cessation
- 1999-12-21 OA OA1200100180A patent/OA11746A/en unknown
- 1999-12-21 TR TR2001/02030T patent/TR200102030T2/xx unknown
- 1999-12-21 AU AU22037/00A patent/AU2203700A/en not_active Abandoned
- 1999-12-21 GE GEAP19996050A patent/GEP20032922B/en unknown
2000
- 2000-12-21 US US09/889,059 patent/US6469004B1/en not_active Expired - Fee Related
2001
- 2001-06-22 IS IS5976A patent/IS5976A/is unknown
- 2001-07-12 NO NO20013452A patent/NO20013452L/no not_active Application Discontinuation
- 2001-08-09 BG BG105800A patent/BG105800A/xx unknown
- 2001-08-10 MA MA26293A patent/MA26771A1/fr unknown

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010068738A1 (en)	2008-12-10	2010-06-17	Dana-Farber Cancer Institute, Inc.	Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en)	2010-02-25	2011-09-01	Dana-Farber Cancer Institute, Inc.	Braf mutations conferring resistance to braf inhibitors
EP3028699A1 (en)	2010-02-25	2016-06-08	Dana-Farber Cancer Institute, Inc.	Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en)	2012-05-08	2013-11-14	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number	Publication date
EE200100373A (et)	2002-10-15
WO2000042022A1 (en)	2000-07-20
BR9916904A (pt)	2001-10-30
CN1333754A (zh)	2002-01-30
ID30439A (id)	2001-12-06
HRP20010524A2 (en)	2002-08-31
AP2001002224A0 (en)	2001-09-30
TR200102030T2 (tr)	2002-01-21
GEP20032922B (en)	2003-03-25
HK1041697A1 (zh)	2002-07-19
ES2247859T3 (es)	2006-03-01
CA2355470A1 (en)	2000-07-20
SK9832001A3 (en)	2003-02-04
ATE302193T1 (de)	2005-09-15
OA11746A (en)	2005-05-13
EA200100772A1 (ru)	2002-02-28
DE69926800D1 (de)	2005-09-22
HUP0105113A2 (hu)	2002-04-29
JP2002534510A (ja)	2002-10-15
IL144214A0 (en)	2002-05-23
YU49401A (sh)	2004-07-15
EP1144385A1 (en)	2001-10-17
DE69926800T2 (de)	2006-05-18
CA2355470C (en)	2008-09-30
HUP0105113A3 (en)	2004-11-29
US6469004B1 (en)	2002-10-22
JP4621355B2 (ja)	2011-01-26
NZ513433A (en)	2003-05-30
CZ20012498A3 (cs)	2002-08-14
NO20013452D0 (no)	2001-07-12
KR20020002370A (ko)	2002-01-09
BG105800A (en)	2002-03-29
IS5976A (is)	2001-06-22
EP1144385B1 (en)	2005-08-17
AU2203700A (en)	2000-08-01
MA26771A1 (fr)	2004-12-20
CN1177830C (zh)	2004-12-01

Publication	Publication Date	Title
NO20013452L (no)	2001-07-12	Benzoheterocykler og deres anvendelse som MEK-inhibitorer
DK1133477T3 (da)	2004-06-21	Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
NO20026010D0 (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20021449L (no)	2002-05-07	Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
NO20021253L (no)	2002-04-24	Kinolylpropylpiperidinderivater og deres anvendelse som antibakterielle midler
NO20014135L (no)	2001-09-27	Nye sulfonamidforbindelser og deres anvendelse
DK1177178T3 (da)	2005-05-02	Heterocyclisk substituerede benzimidazoler, deres fremstilling og anvendelse
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20001079L (no)	2000-09-04	Kopolymerer og deres anvendelse som borehjelpemiddel
DK1198454T3 (da)	2006-06-12	Multilinderivater og deres anvendelse som antibakterielle midler
DK1240164T3 (da)	2004-03-01	Benzazolderivater og deres anvendelse som JNK-modulatorer
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20040469L (no)	2004-04-30	Heterocykliske forbindelser samt fremstilling og anvendelse derav
NO20044062L (no)	2004-10-26	N-aryl-2-oksazolidinon-5-karboksamider og deres derivater og deres anvendelse som antibakterielle midler
NO20001323D0 (no)	2000-03-14	Dipeptid-apoptose inhibitorer og deres anvendelse
DE60032898D1 (de)	2007-02-22	Arylthiazolidindion- und aryloxazolidinderivate
DK1183251T3 (da)	2004-06-07	Indolylpiperidinderivater som antihistamin- og antiallergimidler
IS6413A (is)	2002-06-11	Setnir 8-arýkínólín fosfódíesterasa-4 latar
DK0888316T3 (da)	2000-11-27	2-(3H)-oxazolonderivater og deres anvendelse som cox-2 inhibitorer
DK1150996T3 (da)	2008-02-11	Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
DK1214302T3 (da)	2004-02-16	Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20001718D0 (no)	2000-04-03	Benzen-fusjonerte heterocykliske derivater og anvendelse derav
DK1330453T3 (da)	2006-08-07	Indolylpiperidinderivater som antihistamin- og anti-allergimidler
NO20025884L (no)	2003-01-29	2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
NO20003199D0 (no)	2000-06-20	Benzo(C)kinolizinderivater og deres anvendelse som 5- <alfa>reduktaseinhibitorer

Legal Events

Date	Code	Title	Description
2006-01-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application